Responses
Clinical and epidemiological research
Extended report
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
Compose a Response to This Article
Other responses
No responses have been published for this article.